Allevi is one of the most dynamically developing companies in the 3D bioprinting industry. For years, it has been creating its own bioprinters working with various types of hydrogel materials, and has recently been developing bioprinting process management software. At the same time, Allevi is trying to expand the database of available materials for bioprinting. The company has now decided to work with Lonza Biosciences, a Swiss biotechnology company that will assist Allevi in creating a new bioink.
Together they will focus on developing a material adapted for direct 3D bioprinting that will ensure high cell survival. As part of the cooperation, Allevi customers will have easier access to the Swiss company’s products. Combining Lonza biotechnology solutions with Allevi’s technological capabilities is intended to facilitate the work of scientists and enable reliable research results.
Only a few years ago, as the biggest problem faced by manufacturers from the 3D bioprinting industry, the possibility of creating comprehensive bioprints enriched with blood vessels was given. With the development of technology, scientists have found a number of ways to deal with this problem by bioprinting the first functioning organs. Currently, the availability of materials that guarantee an appropriate environment for cell development is another major obstacle to overcome, which is why this is the main direction of development for companies in the 3D bioprinting industry.
Allevi solutions are very popular among scientists from around the world. The ecosystem, which includes devices, materials and compatible software, is used in research in the field of tissue engineering or helps in the search for new treatment methods.
In turn, Lonza Biosciences is a global leader in the field of biotechnology and cell biology solutions. Their offer includes stem cells, which can be successfully used in creating cell cultures or 3D bioprinting processes.